CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety. joms [Internet]. 2026 Sep. 7 [cited 2026 Sep. 24];21(2):30-5. Available from: https://sebhau.edu.ly/journal/joms/article/view/4892